On July 31, 2026, the Board of Directors approved a reverse stock split at a ratio of one-for-three. The transaction becomes effective on September 1, 2026, with split-adjusted trading commencing that day under symbol NIVF and new CUSIP G0544E154. Outstanding Class A Ordinary Shares will decrease from approximately 6,307,870 to roughly 2,102,623. Fractional shares are consolidated into whole shares rather than cashed out. Convertible securities are adjusted by dividing share counts by three. NewGenIvf Group Limited operates in the fertility and reproductive health services industry.

NewGenIVF Group Limited announced that its total outstanding Class A shares increased to 5,919,948 following issuances related to strategic share purchase agreements for a 3% equity interest in K25.ai. Based on the July 30, 2026 closing price of $0.85, the company's market value of listed securities was US$5,031,956. NewGenIVF Group Limited operates in the healthcare sector, specifically focusing on fertility and reproductive health services.

NewGenIVF Group Limited reported a net profit of US$9.9 million and net assets of approximately US$25.98 million for the fiscal year ended December 31, 2025. The company's 13% stake in K25.ai is now valued at approximately US$26 million based on an implied valuation of US$200 million following a Series A round, representing an unrealized gain of about US$8.5 million. Total shares outstanding are expected to reach 5.9 million after the issuance of 2.5 million Class A ordinary shares announced on July 27, 2026. NewGenIVF Group Limited is a technology-driven diversified growth company operating in real estate development, digital asset innovation, and reproductive health solutions.

NewGenIvf Group Limited entered into a share purchase agreement on July 27, 2026, to acquire an additional 3% equity interest in PredicXion Group Limited (K25.ai) for a total consideration of US$7,500,000. The payment consists of US$3,750,000 in cash or digital assets and 2,500,000 newly issued Class A ordinary shares priced at US$1.50 per share. This transaction increases NewGen's aggregate ownership in K25.ai from 10% to 13% based on a US$250 million equity valuation. The issuance of shares is expected to increase the company's total outstanding shares to approximately 5.9 million, aimed at strengthening market capitalization for Nasdaq compliance. NewGenIvf Group Limited is a diversified growth company operating in real estate, digital assets, and reproductive health solutions.

NewGenIvf Group Limited announced a reverse stock split of all issued and unissued shares at a ratio of one for three. The transaction reduces outstanding Class A Ordinary Shares from 10,259,764 to approximately 3,419,922. The split becomes effective at 12:01 a.m. ET on July 6, 2026, with shares trading on the Nasdaq Capital Market on a split-adjusted basis under the symbol NIVF and a new CUSIP G0544E501. Options, warrants, and convertible securities will be adjusted accordingly, and fractional shares will be rounded up to the nearest full share. The company operates in the healthcare industry, providing fertility services.